Target intelligence / Profile preview

Nucleophilic residue

Molecular classification
Amino acid residue, Protein structural motif, Chemical functional group
01

Overview

Nucleophilic residues are specific amino acid side chains within a protein that possess electron-rich functional groups, such as the thiol of cysteine, the amine of lysine, or the hydroxyl of serine and tyrosine [1, 3]. These residues are critical for biological function, often serving as catalytic centers in enzymes or as sites for essential post-translational modifications like phosphorylation and ubiquitination [3, 12]. In the context of drug discovery, they are the primary sites for covalent inhibitors, which utilize electrophilic "warheads" to form permanent chemical bonds with the residue's nucleophilic center [7, 10]. This mechanism of action allows for prolonged target engagement and high potency, even against proteins with shallow or otherwise "undruggable" binding pockets [7, 8]. However, the ubiquity of these residues across the proteome necessitates high selectivity in drug design to avoid off-target reactivity and associated toxicities [9, 10]. Consequently, "nucleophilic residues" represents a broad chemical classification of reactive sites within proteins rather than a single, discrete therapeutic target [14].

Other names
Nucleophilic amino acidReactive residueCovalent siteElectron-rich side chainNucleophilic side chain
02

Mechanism of action

Drugs target these residues through covalent bond formation, where the nucleophilic group on the amino acid side chain (such as a thiol or amine) attacks an electrophilic warhead on the drug molecule, resulting in irreversible or slowly reversible inhibition of the protein's activity.

03

Biological functions

Enzymatic catalysisPost-translational modificationSignal transductionProtein foldingProtein-protein interaction
04

Disease associations

CancerAutoimmune diseaseInfectionInflammationNeurodegenerative disease
05

Safety considerations

Off-target reactivity with non-target proteinsHapten formation and subsequent immunogenicityIdiosyncratic drug toxicitySystemic toxicity from non-specific covalent bindingHypersensitivity reactions
06

Interacting drugs

Aspirin

8 more in the full profile.

07

Biomarkers

Target occupancy (via Mass Spectrometry)Activity-based protein profiling (ABPP) signalResidue-specific covalent modification status

Beyond the preview

Go deeper on Nucleophilic residue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nucleophilic residue.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call